Xian Jin

Dr. Xian Jin


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
ZZZhong’e Zhou
Zhong’e Zhou
YTYong Tang
Yong Tang
XJXian Jin
Xian Jin
CCChengjun Chen
Chengjun Chen
YLYi Lu
Yi Lu
CSChengxing Shen
Chengxing Shen
Advanced glycation end products (AGEs) are major inflammatory mediators in diabetes, affecting atherosclerosis progression via macrophages. Metformin slows diabetic atherosclerosis progression through mechanisms that remain to be fully elucidated. The present study of murine bone marrow derived macrophages showed that (1) AGEs enhanced proinflammatory cytokines (interleukin-1β(IL-1β), IL-6, and tumor necrosis factor-α(TNF-α)) mRNA expression, RAGE expression, and NFκB activation; (2) metformin pretreatment inhibited AGEs effects and AGEs-induced cluster designation 86 (CD86) (M1 marker) expression, while promoting CD206 (M2 marker) surface expression and anti-inflammatory cytokine (IL-10) mRNA expression; and (3) the AMPK inhibitor, Compound C, attenuated metformin effects. In conclusion, metformin inhibits AGEs-induced inflammatory response in murine macrophages partly through AMPK activation and RAGE/NFκB pathway suppression.

1 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XJXian Jin
Xian Jin
CCChengjun Chen
Chengjun Chen
DLDandan Li
Dandan Li
QSQian Su
Qian Su
YHYanwen Hang
Yanwen Hang
WHWei Hu
Wei Hu
Peroxiredoxin 2 (PRDX2) is an antioxidant and molecular chaperone that can be secreted from tumor cells. But the role of PRDX2 in acute myocardial infarction (AMI) is not clear. In the current study, we demonstrate the role of PRDX2 from clinical trials, H9c2 cells and in a mouse model. ELISA analysis shows that serum concentrations of VEGF and inflammatory factor IL-1β, TNF-α and IL-6 were increased in AMI patients compared to a control group. The expression of PRDX2 was also upregulated. In vivo experiments show that the expression of PRDX2 inhibits hypoxia-induced oxidative stress injury to H9c2 cells. However, PRDX2 expression promotes TLR4 mediated inflammatory factor expression and VEGF expression under hypoxia conditions. PRDX2 overexpression in H9c2 cells also promotes human endothelial cell migration, vasculogenic mimicry formation and myocardial hypertrophy related protein expression. The overexpression of PRDX2 inhibits ROS level and myocardial injury after AMI but promotes inflammatory responses in vivo. Immunocytochemistry and immunofluorescence analysis show that overexpression of PRDX2 promotes angiogenesis and myocardial hypertrophy. Taken together, our results indicate that PRDX2 plays two roles in acute infarction – the promotion of cell survival and inflammatory myocardial hypertrophy.

17 July 2025 in Advanced Science
Verified
Journal Article
Open access
ZWZhixiang Wang
Zhixiang Wang
KNKaifan Niu
Kaifan Niu
WLWei Liu
Wei Liu
XWXinyun Wang
Xinyun Wang
BYBoshen Yang
Boshen Yang
XJXian Jin
Xian Jin
Progressive cardiac fibrosis post myocardial infarction (MI) drives pathological remodeling and heart failure, yet the role of endoplasmic reticulum‐selective autophagy (ER‐phagy) in this process remains unclear. Autocrine Motility Factor Receptor (AMFR) is a recently identified ER‐phagy regulator, whose function under myocardial pathology remains poorly understood. Here, it is found that FAM134B‐mediated ER‐phagy activity is elevated in fibrotic mouse heart tissues post‐MI and in cardiac fibroblasts stimulated by TGF‐β1. AMFR knockout in mice aggravated cardiac fibrosis post‐MI and worsened cardiac function, with scRNA‐seq analysis demonstrating that AMFR‐null cardiac fibroblasts exhibit a myofibroblast phenotype. Simultaneously, AMFR overexpression in cardiac fibroblasts reduces the expression of profibrogenic proteins in response to TGF‐β1 stimulation. AMFR regulates ER‐phagy flux and turnover of FAM134B, which leads to the suppression of cardiac fibroblasts activation. Mechanistically, AMFR catalyzed K27‐linked (predominant) and K33‐linked ubiquitination of FAM134B and enhanced ER‐phagy flux, thereby inhibiting the phosphorylation of mTORC1 downstream targets such as S6K1 and 4E‐BP. These findings highlight the therapeutic potential of AMFR‐driven ER‐phagy in suppressing cardiac fibrosis post‐MI.

22 March 2018 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
XJXian Jin
Xian Jin
LLLiang Liu
Liang Liu
YZYaping Zhang
Yaping Zhang
YXYin Xiang
Yin Xiang
GYGuizhi Yin
Guizhi Yin
CSChengxing Shen
Chengxing Shen
Objective. Increased monocytes, particularly the inflammatory subset, are associated with accelerated atherosclerosis in diabetes through thus far incompletely defined mechanisms. The present study tested the hypothesis that advanced glycation end products (AGEs) promote bone marrow monocytes to proliferate and drive them into an inflammatory phenotype.Methods and Results. In vivo, AGEs (25 mg/kg i.p. for 7 days) increased proportions of CD115+monocytes and the inflammatory subset, the CD115+Ly6Chighcells, in murine bone marrow (flow cytometry analysis (FCM)), and enhanced gene expression of proinflammatory cytokines (IL-1βand TNF-α) but only slightly upregulated mRNA expression of anti-inflammatory cytokine (IL-10) (real-time PCR) in monocytes. In vitro, when the monocytes were treated with different dosages of AGEs (50, 150, and 300 μg/mL), we found that proliferation (CCK8) but not apoptosis (FCM) of the monocytes was induced; the mRNA expressions of proinflammatory cytokines (IL-1βand TNF-α) and GM-CSF were upregulated in a dose-dependent manner while mRNA levels of IL-10 and M-CSF were changed much less in monocytes (real-time PCR). Furthermore, AGEs (300 μg/mL) significantly enhanced the expression of Ki67 in monocytes (immunofluorescence staining (IF)), and this dose of AGEs markedly increased secretion of GM-CSF but not that of M-CSF (ELISA). For a pathway study, the monocytes were stimulated by 300 μg/mL AGEs for different periods of time (0, 15, 30, and 120 min) and the activation of the MAPK pathway was tested (FCM); the results showed the p38 and ERK pathways were activated but not JNK signaling. Pretreatment with an inhibitor of p38 (SB203580) or ERK (U0126) attenuated AGE-induced gene expression of proinflammatory cytokines and GM-CSF (real-time PCR), as well as reversing AGE-induced Ki67 expression (IF).Conclusions. AGEs promote bone marrow monocytes to proliferate and drive them into an inflammatory phenotype through p38 and ERK activation.

3 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
XWXinyun Wang
Xinyun Wang
YLYangyi Lin
Yangyi Lin
WLWei Liu
Wei Liu
YWYufeng Wu
Yufeng Wu
BYBoshen Yang
Boshen Yang
XJXian Jin
Xian Jin
Background: Emerging evidence has established ferroptosis as a vital factor in the pathogenesis of cardiovascular diseases, especially in septic cardiomyopathy (SCM). Meanwhile, ondansetron (OND), a well-established 5-HT3 receptor antagonist, has gained increasing attention for its pleiotropic effects. However, its potential to modulate ferroptosis in the cardiovascular field remains unexplored. This study aims to fill this gap by exploring the potential of OND as an innovative therapeutic intervention for SCM. Methods: This study utilized both in vitro and in vivo models of septic cardiomyopathy (SCM), which was induced by lipopolysaccharide (LPS) stimulation in neonatal rat cardiomyocytes (NRCMs) and C57BL/6 mice. Through RNA sequencing, as well as molecular and functional assessments—including echocardiography and ferroptosis-related measurements—we revealed the anti-ferroptotic effect of ondansetron (OND). Mechanistically, ATF3 was identified as a pivotal regulator, with its overexpression via AAV9 in vivo and ADV in vitro confirming its role in OND-induced cardioprotection. Results: Ondansetron (OND) showed potent anti-ferroptotic effects in both cellular and murine models of septic cardiomyopathy (SCM). Treatment with OND not only improved cardiac performance but also reduced ferroptotic markers, mitigated lipid peroxidation and iron overload, and bolstered antioxidant defense. Notably, OND administration attenuated oxidative and endoplasmic reticulum (ER) stress while restoring mitochondrial integrity. Mechanistically, the anti-ferroptotic activity of OND was mediated through the HTR3A/ATF3 axis: ATF3 overexpression negated OND’s protective effects, while HTR3A antagonism with VUF10166 recapitulated its benefits. Conversely, HTR3A agonism with PBG attenuated ferroptosis resistance, further implicating this pathway as central to OND’s mechanism. Conclusions: This study demonstrated a novel pharmacological role for ondansetron (OND) in attenuating ferroptosis in septic cardiomyopathy (SCM) via the HTR3A/ATF3 signaling pathway. This finding delineates a novel therapeutic avenue and supports the repurposing of OND beyond its traditional antiemetic use to cardiovascular applications.